MA43794B1 - Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie - Google Patents

Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie

Info

Publication number
MA43794B1
MA43794B1 MA43794A MA43794A MA43794B1 MA 43794 B1 MA43794 B1 MA 43794B1 MA 43794 A MA43794 A MA 43794A MA 43794 A MA43794 A MA 43794A MA 43794 B1 MA43794 B1 MA 43794B1
Authority
MA
Morocco
Prior art keywords
methods
immunotherapy
predicting
tumor
neoantigens
Prior art date
Application number
MA43794A
Other languages
English (en)
Other versions
MA43794A (fr
Inventor
Ugur Sahin
Mathias Vormehr
Barbara Schrörs
Martin Löwer
Sebastian Boegel
Original Assignee
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Rna Pharmaceuticals Gmbh filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Publication of MA43794A publication Critical patent/MA43794A/fr
Publication of MA43794B1 publication Critical patent/MA43794B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés de prédiction de l'utilité de peptides ou de polypeptides tels que des épitopes de lymphocytes t pour l'immunothérapie, par exemple pour la vaccination. En particulier, la présente invention concerne des procédés pour prédire si des peptides ou des polypeptides tels que des antigènes ou des épitopes associés à une tumeur, en particulier des néoantigènes ou néoépitopes associés à une tumeur, sont immunogènes et, en particulier, utiles pour l'immunothérapie, par exemple pour la vaccination. Les procédés selon l'invention peuvent être utilisés en particulier pour fournir des vaccins qui sont spécifiques d'une tumeur d'un patient et, donc, dans le contexte de vaccins anticancéreux personnalisés.
MA43794A 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie MA43794B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (fr) 2016-05-13 2016-05-13 Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie
PCT/EP2017/061196 WO2017194610A1 (fr) 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de protéines ou de fragments de protéines pour l'immunothérapie

Publications (2)

Publication Number Publication Date
MA43794A MA43794A (fr) 2019-03-20
MA43794B1 true MA43794B1 (fr) 2020-12-31

Family

ID=55971007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43794A MA43794B1 (fr) 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie

Country Status (26)

Country Link
US (1) US20190178871A1 (fr)
EP (3) EP3792628B1 (fr)
JP (4) JP7529381B2 (fr)
KR (3) KR20220020993A (fr)
CN (1) CN109073637A (fr)
AU (2) AU2017264546B2 (fr)
BR (1) BR112018073221A2 (fr)
CA (1) CA3022654A1 (fr)
CY (1) CY1123520T1 (fr)
DK (2) DK3455625T3 (fr)
ES (2) ES2980781T3 (fr)
FI (1) FI3792628T3 (fr)
HR (2) HRP20240704T1 (fr)
HU (1) HUE052240T2 (fr)
IL (2) IL300841A (fr)
LT (2) LT3455625T (fr)
MA (1) MA43794B1 (fr)
MD (1) MD3455625T2 (fr)
MX (2) MX2018013081A (fr)
PL (2) PL3455625T3 (fr)
PT (2) PT3792628T (fr)
RS (2) RS65568B1 (fr)
SG (1) SG11201808495SA (fr)
SI (2) SI3792628T1 (fr)
WO (2) WO2017194170A1 (fr)
ZA (1) ZA201805809B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3400004A1 (fr) 2016-01-08 2018-11-14 Vaccibody AS Vaccin thérapeutique anticancéreux à néoépitope
EP3631471A4 (fr) 2017-05-30 2021-06-30 Nant Holdings IP, LLC Enrichissement de cellules tumorales circulantes à l'aide de néo-épitopes
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
KR20210137110A (ko) * 2019-03-06 2021-11-17 그릿스톤 바이오, 인코포레이티드 Mhc 클래스 ii 모델을 사용한 신생항원 동정
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399B (zh) * 2020-03-26 2021-09-17 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
WO2023025404A1 (fr) 2021-08-24 2023-03-02 BioNTech SE Technologies de transcription in vitro
WO2024083345A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Procédés et utilisations associés à des compositions liquides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CA2603191A1 (fr) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Vaccins contre le cancer et methodes therapeutiques
JP2009273377A (ja) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP2490713A2 (fr) * 2009-10-23 2012-08-29 MannKind Corporation Immunothérapie pour le cancer et procédé de traitement du cancer
EP2714730A1 (fr) * 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau peptide antigénique et ses utilisations

Also Published As

Publication number Publication date
AU2017264546A1 (en) 2018-10-18
EP3455625A1 (fr) 2019-03-20
MA43794A (fr) 2019-03-20
AU2022209286A1 (en) 2022-08-25
RU2018137721A (ru) 2020-06-15
KR20190008218A (ko) 2019-01-23
LT3455625T (lt) 2021-01-11
KR102358620B1 (ko) 2022-02-07
HRP20240704T1 (hr) 2024-09-27
EP4411376A2 (fr) 2024-08-07
KR20220020993A (ko) 2022-02-21
EP3792628A3 (fr) 2021-05-19
SI3455625T1 (sl) 2021-01-29
EP3455625B1 (fr) 2020-09-02
PT3455625T (pt) 2020-10-22
IL262680B2 (en) 2023-08-01
WO2017194610A1 (fr) 2017-11-16
IL262680A (en) 2018-12-31
JP2024112805A (ja) 2024-08-21
JP2022081492A (ja) 2022-05-31
JP2019520554A (ja) 2019-07-18
RU2018137721A3 (fr) 2020-08-25
PT3792628T (pt) 2024-06-18
BR112018073221A2 (pt) 2019-02-19
SI3792628T1 (sl) 2024-08-30
LT3792628T (lt) 2024-06-25
ES2826480T3 (es) 2021-05-18
HUE052240T2 (hu) 2021-04-28
CY1123520T1 (el) 2022-03-24
MX2018013081A (es) 2019-01-24
ZA201805809B (en) 2020-12-23
CA3022654A1 (fr) 2017-11-16
JP7529381B2 (ja) 2024-08-06
SG11201808495SA (en) 2018-10-30
KR20240146087A (ko) 2024-10-07
MD3455625T2 (ro) 2020-12-31
FI3792628T3 (fi) 2024-06-07
EP3792628B1 (fr) 2024-04-24
IL300841A (en) 2023-04-01
PL3455625T3 (pl) 2021-01-25
RS61071B1 (sr) 2020-12-31
IL262680B1 (en) 2023-04-01
CN109073637A (zh) 2018-12-21
DK3792628T3 (da) 2024-06-17
DK3455625T3 (da) 2020-10-26
WO2017194170A1 (fr) 2017-11-16
EP3792628A2 (fr) 2021-03-17
JP2024096712A (ja) 2024-07-17
RS65568B1 (sr) 2024-06-28
ES2980781T3 (es) 2024-10-03
US20190178871A1 (en) 2019-06-13
HRP20201671T1 (hr) 2021-03-05
PL3792628T3 (pl) 2024-07-15
AU2017264546B2 (en) 2022-04-28
MX2022007902A (es) 2022-07-21

Similar Documents

Publication Publication Date Title
MA43794B1 (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA43458A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
CR20200465A (es) Agentes anticuerpos anti-cd25
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA46507A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
WO2018098306A8 (fr) Blocage de l'expression de cd7 et récepteurs d'antigènes chimériques pour l'immunothérapie de malignités de lymphocytes t
PH12018502250A1 (en) Cancer immunotherapy by immune activation for immune modulation via globo series antigens
MA41717A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
EA201791853A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
MA31093B1 (fr) Vaccin
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
CR20200608A (es) INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
CR20210067A (es) NUEVOS PÉPTIDOS Y ESTRUCTURAS DE SOPORTE PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CARCINOMA EPIDERMOIDE DE CABEZA Y CUELLO Y OTROS DE CÁNCER (Divisional 2019-0094)
PH12020551454A1 (en) Anti-cd25 for tumour specific cell depletion
MX2022000379A (es) Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas.
MX2021000853A (es) Vacunas individualizadas para el cancer.
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
MA49155B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MX2024006208A (es) Anticuerpo anti-trem2 y usos del mismo.